2018's best-sellers? AbbVie's Humira, obviously, but newcomers are on their way
admin 20th December 2017 Uncategorised 0Anyone hoping for an upheaval at the top of pharma’s drug sales charts next year will have to keep waiting. AbbVie’s $20 billion behemoth Humira will continue to dominate in 2018, with Celgene’s Revlimid a distant second. Among the stalwarts: Merck’s immunotherapy Keytruda.
More: 2018's best-sellers? AbbVie's Humira, obviously, but newcomers are on their way
Source: fierce